REG - C4X Discovery - Grant of options and Directors Dealing

C4X Discovery HoldingsAnnouncement

14/12/2020 17:15

RNS Number : 6161I
  
C4X Discovery Holdings PLC
  
14 December 2020
  
 

C4X Discovery Holdings plc
 
("C4XD", "C4X Discovery" or the "Company")
 
Grant of options and Directors Dealing
 
 
14 December 2020 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that a total of 600,000 options over ordinary shares of the Company were awarded pursuant to the EMI 2014 Plan to certain employees, which includes 200,000 options each to Dr Clive Dix, Chief Executive Officer, Dr Craig Fox, Chief Scientific Officer and Brad Hoy, Chief Financial Officer, as set out below. 
 



Director


Position


Number of share options awarded


Option exercise price per share (pence)


Total number of options held




Dr Clive Dix


Chief Executive Officer


200,000


20


645,000




Dr Craig Fox


Chief Scientific officer


200,000


20


700,000




Brad Hoy


Chief Financial Officer


200,000


20


800,000



 
The options have an exercise price of 20 pence, being the average 5-day VWAP of the ordinary shares to the 11 December 2020.  The options can be exercised at any time between three and 10 years of them being granted.
 
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
 
Notification and public disclosure of transactions by person discharging managerial responsibilities and persons closely associated with them.
 



1


Details of the person discharging managerial responsibilities/person closely associated




a)


Name(s)
 


Dr Clive Dix




2


Reason for the notification





a)



Position/status
 


Chief Executive Officer, Director




b)


Initial notification/Amendment
 


Initial Notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


C4X Discovery Holdings plc




b)


LEI


213800UHNL82E323O870




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument
 
Identification code

 


Options over ordinary shares of one penny (£0.01) each in the share capital of the Company - EMI 2014 Plan
 
 
ISIN GB00BQQ2RV18




b)


Nature of the transaction
 


Grant of options over ordinary shares




c)


Price(s) and volume(s)
 
 





Price(s)


Volume(s)




20p


200,000



 




d)


Aggregated information
 








e)


Date of the transaction
 


14 December 2020




f)


Place of the transaction
 
 


London Stock Exchange - AIM



 



1


Details of the person discharging managerial responsibilities/person closely associated




a)


Name
 


Dr Craig Fox




2


Reason for the notification





a)



Position/status
 


Chief Scientific Officer, Director




b)


Initial notification/Amendment
 


Initial Notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


C4X Discovery Holdings plc




b)


LEI


213800UHNL82E323O870




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument
 
Identification code

 


Options over ordinary shares of one penny (£0.01) each in the share capital of the Company - EMI 2014 Plan
 
 
ISIN GB00BQQ2RV18




b)


Nature of the transaction
 


Grant of options over ordinary shares




c)


Price(s) and volume(s)
 
 





Price(s)


Volume(s)




20p


200,000



 




d)


Aggregated information
 








e)


Date of the transaction
 


14 December 2020




f)


Place of the transaction
 
 


London Stock Exchange - AIM



 



1


Details of the person discharging managerial responsibilities/person closely associated




a)


Name
 


Brad Hoy




2


Reason for the notification





a)



Position/status
 


Chief Financial Officer, Director




b)


Initial notification/Amendment
 


Initial Notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


C4X Discovery Holdings plc




b)


LEI


213800UHNL82E323O870




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument
 
Identification code

 


Options over ordinary shares of one penny (£0.01) each in the share capital of the Company - EMI 2014 Plan
 
 
ISIN GB00BQQ2RV18




b)


Nature of the transaction
 


Grant of options over ordinary shares




c)


Price(s) and volume(s)
 
 





Price(s)


Volume(s)




20p


200,000



 




d)


Aggregated information
 








e)


Date of the transaction
 


14 December 2020




f)


Place of the transaction
 
 


London Stock Exchange - AIM



 
 
- Ends -
 
Contacts
 



C4X Discovery Holdings








Mo Noonan, Communications


+44 (0)787 6444977














Panmure Gordon (UK) Limited (NOMAD and Broker) 








Freddy Crossley, Emma Earl (Corporate Finance)


+44 (0)20 7886 2500




Rupert Dearden (Corporate Broking)


















C4X Discovery Media - Consilium Strategic Communications








Mary-Jane Elliott, Chris Gardner, Matthew Neal


+44 (0)203 709 5700



 
 




 
Notes to Editors:
 
About C4X Discovery
C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m, which is now in a Phase I clinical study.
 
C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.
 
For additional information please go to: www.c4xdiscovery.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHUSABRROUUAAA